
The contribution of endogenous glucagon‐like peptide (GLP)‐1 to β‐cell function after Roux‐en‐Y gastric bypass surgery (RYGB) is well established in normoglycaemic individuals, but not in those with postoperative hyperglycaemia. Therefore, studied the effect of GLP‐1 on β‐cell function in individuals with varying degrees of type 2 diabetes mellitus (T2D) control after RYGB. GLP‐1 blockade reversed the improvement in β‐cell function observed after RYGB, but this effect varied temporally and by REM status. GLP‐1 blockade transiently and minimally worsened glycaemia only in REM, and lowered postprandial glucose values at 3 months, regardless of REM status.
Like
Save
Share